Evidence map›Paper›PMID 25924235›Full record

ArticleOncotarget2015

Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling.

Ghizlane Khalfaoui-Bendriss, Nadège Dussault, Samantha Fernandez-Sauze, Caroline Berenguer-Daizé, Romain Sigaud, Christine Delfino, Mylène Cayol, Philippe Metellus, Olivier Chinot, Kamel Mabrouk and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Adrenomedullin in Tumorigenesis and Cancer Progression.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ghizlane Khalfaoui-BendrissAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Nadège DussaultAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Samantha Fernandez-SauzeAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Caroline Berenguer-DaizéAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Romain SigaudAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Christine DelfinoAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Mylène CayolAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Philippe MetellusAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Olivier ChinotAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Kamel MabroukAix-Marseille Université, CNRS, UMR 7273, Institut de Chimie Radicalaire (ICR) Marseille, France.
Pierre-Marie MartinAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
L'Houcine OuafikAix Marseille Université, CRO2, UMR_S 911, Faculté de Médecine, Marseille, France.
Aix-Marseille Université · FRHôpital Nord · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cellular and molecular mechanisms by which adrenomedullin (AM) blockade suppresses tumor neovessels are not well defined. Herein, we show that AM blockade using anti-AM and anti-AM receptors antibodies targets vascular endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), and induces regression of unstable nascent tumor neovessels. The underlying mechanism involved, and shown in vitro and in vivo in mice, is the disruption of the molecular engagement of the endothelial cell-specific junctional molecules vascular endothelial-cadherin (VE-cadherin)/β-catenin complex. AM blockade increases endothelial cell permeability by inhibiting cell-cell contacts predominantly through disruption of VE-cadherin/β-catenin/Akt signalling pathway, thereby leading to vascular collapse and regression of tumor neovessels. At a molecular level, we show that AM blockade induces tyrosine phosphorylation of VE-cadherin at a critical tyrosine, Tyr731, which is sufficient to prevent the binding of β-catenin to the cytoplasmic tail of VE-cadherin leading to the inhibition of cell barrier function. Furthermore, we demonstrate activation of Src kinase by phosphorylation on Tyr416, supporting a role of Src to phosphorylate Tyr731-VE-cadherin. In this model, Src inhibition impairs αAM and αAMR-induced Tyr731-VE-cadherin phosphorylation in a dose-dependent manner, indicating that Tyr731-VE-cadherin phosphorylation state is dependent on Src activation. We found that AM blockade induces β-catenin phosphorylation on Ser33/Ser37/Thr41 sites in both ECs and VSMCs both in vitro and in vivo in mice. These data suggest that AM blockade selectively induces regression of unstable tumor neovessels, through disruption of VE-cadherin signalling. Targeting AM system may present a novel therapeutic target to selectively disrupt assembly and induce regression of nascent tumor neovessels, without affecting normal stabilized vasculature.

Indexed as

AdrenomedullinAnimalsbeta CateninEndothelium, VascularHumansMiceMice, NudeNeovascularization, PhysiologicPhosphorylationSignal TransductionAdrenomedullinbeta Cateninadrenomedullinangiogenesistumor neovesselsVE-cadherinβ-catenin

Identifiers

PMID25924235
PMCPMC4480698
OpenAlexW1963178508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.